Evidence map›Paper›PMID 26490751›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2016

[(18)F]FPRGD2 PET/CT imaging of integrin αvβ3 levels in patients with locally advanced rectal carcinoma.

Nadia Withofs, Philippe Martinive, Jean Vanderick, Noëlla Bletard, Irène Scagnol, Frédéric Mievis, Fabrice Giacomelli, Philippe Coucke, Philippe Delvenne, Didier Cataldo and 2 more

Abstract readComparative StudyEvaluation Study
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. European journal of nuclear medicine and molecular imaging · 2019
    Article
  5. Perspectives: MRI of angiogenesis.Journal of magnetic resonance (San Diego, Calif. : 1997) · 2018
    Review
  6. A First Report on [Contrast media & molecular imaging · 2017
    Observational
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Nadia WithofsDepartment of Medical Physics, Division of Nuclear Medicine and Oncological Imaging, B35 Domaine universitaire du Sart Tilman, 4000, Liege, Belgium.
Philippe MartiniveDivision of Radiation Oncology, Department of Medical Physics, CHU Liège, Liège, Belgium.
Jean VanderickDivision of Radiation Oncology, Department of Medical Physics, CHU Liège, Liège, Belgium.
Noëlla BletardDepartment of Pathology, CHU Liège, Liège, Belgium.
Irène ScagnolDepartment of Pathology, CHU Liège, Liège, Belgium.
Frédéric MievisCYCLOTRON Research Centre, University of Liège, Liège, Belgium.
Fabrice GiacomelliCYCLOTRON Research Centre, University of Liège, Liège, Belgium.
Philippe CouckeDivision of Radiation Oncology, Department of Medical Physics, CHU Liège, Liège, Belgium.
Philippe DelvenneDepartment of Pathology, CHU Liège, Liège, Belgium.
Didier CataldoLaboratory of Tumour and Developmental Biology, GIGA-Research, University of Liège, Liège, Belgium.
Sanjiv S GambhirMolecular Imaging Program at Stanford (MIPS), Radiology Department, Stanford University, Stanford, CA, USA.
Roland HustinxDepartment of Medical Physics, Division of Nuclear Medicine and Oncological Imaging, B35 Domaine universitaire du Sart Tilman, 4000, Liege, Belgium. rhustinx@chu.ulg.ac.be.
University of Liège · BECentre Hospitalier Universitaire de Liège · BEStanford University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeOur primary objective was to determine if [(18)F]FPRGD2 PET/CT performed at baseline and/or after chemoradiotherapy (CRT) could predict tumour regression grade (TRG) in locally advanced rectal cancer (LARC). Secondary objectives were to compare baseline [(18)F]FPRGD2 and [(18)F]FDG uptake, to evaluate the correlation between posttreatment [(18)F]FPRGD2 uptake and tumour microvessel density (MVD) and to determine if [(18)F]FPRGD2 and FDG PET/CT could predict disease-free survival.

methodsBaseline [(18)F]FPRGD2 and FDG PET/CT were performed in 32 consecutive patients (23 men, 9 women; mean age 63 ± 8 years) with LARC before starting any therapy. A posttreatment [(18)F]FPRGD2 PET/CT scan was performed in 24 patients after the end of CRT (median interval 7 weeks, range 3 - 15 weeks) and before surgery (median interval 4 days, range 1 - 15 days).

resultsAll LARC showed uptake of both [(18)F]FPRGD2 (SUVmax 5.4 ± 1.5, range 2.7 - 9) and FDG (SUVmax 16.5 ± 8, range 7.1 - 36.5). There was a moderate positive correlation between [(18)F]FPRGD2 and FDG SUVmax (Pearson's r = 0.49, p = 0.0026). There was a moderate negative correlation between baseline [(18)F]FPRGD2 SUVmax and the TRG (Spearman's r = -0.37, p = 0.037), and a [(18)F]FPRGD2 SUVmax of >5.6 identified all patients with a complete response (TRG 0; AUC 0.84, 95 % CI 0.68 - 1, p = 0.029). In the 24 patients who underwent a posttreatment [(18)F]FPRGD2 PET/CT scan the response index, calculated as [(SUVmax1 - SUVmax2)/SUVmax1] × 100 %, was not associated with TRG. Post-treatment [(18)F]FPRGD2 uptake was not correlated with tumour MVD. Neither [(18)F]FPRGD2 nor FDG uptake predicted disease-free survival.

conclusionBaseline [(18)F]FPRGD2 uptake was correlated with the pathological response in patients with LARC treated with CRT. However, the specificity was too low to consider its clinical routine use.

Indexed as

Peptides, CyclicPositron-Emission TomographyRadiopharmaceuticalsAgedCarcinomaFemaleHumansIntegrin alphaVbeta3MaleMiddle AgedMultimodal ImagingRectal NeoplasmsTomography, X-Ray ComputedFB-mini-PEG-E(c(RGDyK))2Integrin alphaVbeta3Peptides, CyclicRadiopharmaceuticalsAngiogenesisIntegrinPETRectal cancerRGD

Identifiers

PMID26490751
OpenAlexW2192799236

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.